HealthBioMarin To Halt Development Of $680M Duchenne Muscular Dystrophy Drug BioMarin will no longer continue developing Kyndrisa after reports of negative reviews by the European Medicines Agency surfaced. The biotech company, however, will pursue next generation antisense oligonucleotides research.by Catherine Cabral-Isabedra
HealthWHO Rejects Call To Postpone, Cancel Rio Olympics Because Of Zika Virus Threatby Rina Marie Doctor
HealthNew Gene Screening Test To Help Doctors Identify Rare Genetic Diseases In Newbornsby Katrina Pascual